


**Fig. S1** Median B-cell count up to week 48 after first course of treatment (PD population<sup>a</sup>).



<sup>a</sup>Patients who received at least one full dose of CT-P10 or RTX and provided at least one post-treatment PD result.

PD, pharmacodynamics; RTX, innovator rituximab; W, week.

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial. *BioDrugs*. Dae Hyun Yoo, Chang-Hee Suh, Seung Cheol Shim, et al. Corresponding author affiliation and email: Prof. Won Park, IN-HA University, School of Medicine, Incheon, Republic of Korea; parkwon@inha.ac.kr.